Domain Therapeutics appoints chair of board
This article was originally published in Scrip
Strasbourg, France-based Domain Therapeutics, a biopharmaceutical company specializing in the development of new drug candidates targeting G protein-coupled receptors (GPCRs), has named Dr Youssef L Bennani chair of its board of directors. Dr Bennani is currently site head and vice-president of R&D at Vertex Pharmaceuticals' site in Laval, Quebec. He replaces Sam Eletr who held the position of chair of the board from November 2008 to April 2014. Mr Eletr remains a contributing shareholder of Domain.